The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast.
AffiliationDepartment of Surgery, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractHigh body weight is associated with increased production of oestrogens which may influence the clinical behaviour of breast cancer. We have examined the influence of body weight on the response to endocrine therapy, steroid hormone receptor content and survival in 227 women who either presented with or developed advanced cancer of the breast. One hundred and thirty-three (59%) patients presented with operable disease and 94 (41%) with locally advanced tumours. Two hundred (88%) were treated by tamoxifen and 27 (12%) by ovarian ablation. High body weight was correlated with advanced tumour stage (P = 0.002) and progesterone receptor (PR) positivity (P = 0.01), but not with the presence of oestrogen receptor (ER P = 0.21). The association between high body weight and PR positivity was particularly noticeable among ER positive tumours. There was no significant relationship between the nature of the response to therapy and weight (P = 0.57). There was no significant difference in survival from the start of endocrine therapy (P = 0.95), nor the time to progression of disease (P = 0.29) between patients above and below the median weight of 64 kg. Among the patients with operable disease, there was no difference in overall survival (P = 0.42), relapse free survival (P = 0.69), and survival from the start of endocrine therapy (P = 0.85) according to body weight.
CitationThe relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. 1988, 58 (5):631-4 Br J Cancer
JournalBritish Journal of Cancer
- Steroid-hormone receptors and survival after first relapse in breast cancer.
- Authors: Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, Swindell R, Crowther D, Sellwood RA
- Issue date: 1984 Mar 17
- [Steroid hormone receptors in breast cancer].
- Authors: Nomura Y
- Issue date: 1990 Jan
- Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
- Authors: Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, Seidl B, Gibbons K, Pyke C, Shannon C, Woodward N, Armes JE
- Issue date: 2017 Nov
- Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
- Authors: Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG
- Issue date: 1999 Feb
- Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.
- Authors: Howell A, Harland RN, Barnes DM, Baildam AD, Wilkinson MJ, Hayward E, Swindell R, Sellwood RA
- Issue date: 1987 Jan 1